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A B S T R A C T
Introduction: A lack of prospective and longitudinal data on pre- and post-travel carriage of Blastocystis spp.
complicates interpretation of a positive test post-travel. Therefore we studied dynamics of Blastocystis carriage in
a cohort of Dutch travellers.
Methods: From the prospective, multicentre COMBAT study among 2001 Dutch travellers, a subset of 491 tra-
vellers was selected based on travel destination to 7 subregions (70 or 71 travellers each). Faecal samples taken
directly before and after travel were screened for Blastocystis with qPCR, followed, when positive, by sequence
analysis to determine subtypes.
Results: After exclusion of 12 samples with missing samples or inhibited qPCR-reactions, stool samples of 479
travellers were analysed. Before travel, 174 of them (36.3%) carried Blastocystis and in most of these, the same
subtype was persistently carried. However, in 48/174 of those travellers (27.6%; CI95 20.8–36.6%) no
Blastocystis or a diﬀerent subtype was detected in the post-travel sample, indicating loss of Blastocystis during
travel. Only 26 (5.4%; CI95 3.7%–8.0%) of all travellers acquired Blastocystis, including two individuals that
were already positive for Blastocystis before travel but acquired a diﬀerent subtype during travel.
Discussion: This study shows that Blastocystis carriage in travellers is highly dynamic. The observed acquisition
and loss of Blastocystis could either be travel-related or reﬂect the natural course of Blastocystis carriage. We
demonstrate that the majority of Blastocystis detected in post-travel samples were already carried before travel.
1. Introduction
Blastocystis spp. are among the most commonly observed intestinal
protozoan parasites in humans [1]. Thus far, 17 diﬀerent Blastocystis
spp. (or simply Blastocystis) subtypes (STs) have been distinguished
genetically; with ST1, ST2, ST3 and ST4 being the most frequently re-
ported subtypes [2–5]. Of these, ST4 is possibly associated with in-
creased pathogenicity in humans [6]. Simultaneous colonisation with
diﬀerent subtypes is not uncommon. Transmission most often occurs by
the faecal-oral route or through ingestion of contaminated water [6,7].
Since Blastocystis is found in many animal species, zoonotic transmis-
sion may also occur [8–10].
Since asymptomatic carriage is common in humans and results from
previous studies are unclear on whether elimination of the parasite is
associated with clinical improvement. Therefore the pathogenic po-
tential of Blastocystis for humans had been debated for decades [11–14].
It has been demonstrated that the prevalence of Blastocystis in stool
samples submitted for routine parasitological examination of patients
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who returned from tropical countries is signiﬁcantly higher than among
patients without such a travel history [15]. These ﬁndings suggest that
travel is associated with a risk of acquiring Blastocystis. This is parti-
cularly relevant in travel medicine where many travellers return with
abdominal complaints and/or diarrhoea and are tested positive for
Blastocystis. In those cases, clinicians are faced with the dilemma
whether treatment should be oﬀered or not, especially if no other po-
tential pathogen is detected [16].
A wide range of bacteria, viruses and parasites that can be acquired
during travel are associated with traveller's diarrhoea (TD) [17]. Non-
prospective studies in travellers found Blastocystis to be more prevalent
in subjects with TD than in those without TD [18,19] whilst others did
not ﬁnd this diﬀerence [12]. However, prospective and longitudinal
data on acquisition rates of Blastocystis during travel in symptomatic
and asymptomatic travellers are needed to better understand the clin-
ical relevance of Blastocystis detection post travel, but such data are
largely lacking. Therefore we studied pre- and post-travel carriage and
subtype distribution of Blastocystis in a cohort of Dutch international
travellers.
Although hard to realize, sequential and frequent sampling before,
during and after travel would be ideal in understanding colonisation
dynamics of travel related pathogens. In absence of such frequent
samples, mathematical modelling maximizes insight in colonisation
dynamics of Blastocystis and these pathogens in general.
2. Methods
2.1. Study population
The COMBAT-study is a multicentre longitudinal cohort study of
2001 healthy Dutch adults who travelled abroad for a time period of
1–12 weeks. Details of this cohort study have been reported previously
[20,21]. In short, subjects were included from November 2012 until
November 2013. All received a faeces collection swab (Fecal Swab;
Copan, Brescia, Italy) with transport medium and a questionnaire im-
mediately before and after travel. The questionnaires comprised de-
tailed information about previous travel, health, medication use and
details about destination and behaviour during travel. All stool samples
were stored at −80 °C for future analysis.
2.2. Selection of travellers
To be able to determine geographic distribution of acquired
Blastocystis subtypes, seven United Nations' deﬁned geographical sub-
regions that were visited by more than 70 travellers were selected
[Table 1]. After excluding subjects who had travelled to more than one
subregion, 70 travellers were randomly selected from six subregions
and 71 travellers from the remaining one. In total, a subset of 491
travellers was selected from the entire cohort. From these travellers,
pre- and post-travel samples were analysed for the presence of Blas-
tocystis. Subjects of whom one or both samples were missing were ex-
cluded from ﬁnal analyses.
2.3. DNA extraction
Automated nucleic acid extraction was performed using the MagNA
Pure 96 instrument (Roche Applied Science, the Netherlands) according
to the manufacturer's protocol. DNA was eluted in 100 μl elution buﬀer
(Roche Applied Science). Phocine Herpes Virus (PhoHV) DNA was
added to all samples as an internal control (IC) for extraction and
ampliﬁcation eﬃciency.
2.4. Testing for Blastocystis
Presence of Blastocystis infection was assessed by real-time PCR
targeting the small subunit ribosomal RNA gene (SSU-rDNA) [22].
Positive controls consisting of a plasmid containing the target sequence
were included in every run, as well as negative extraction controls and
negative PCR controls. Subjects were excluded from further analyses if
IC's tested negative in one or more samples.
For subtyping of Blastocystis and conﬁrmation of the presence of
Blastocystis DNA in samples, PCR-amplicons were sequenced using se-
parate primers. Both DNA strands of amplicons were sequenced with
BigDye™ Terminator chemistry (Applied Biosystems) and analysed on
an ABI 3900 sequencer (Applied Biosystems). Obtained sequences were
aligned to Genbank® reference sequences using CodonCode Aligner
program (CodonCode Corporation) and MEGA 6.0 [23]. Subtypes were
identiﬁed according to the nomenclature proposed by Stensvold et al.
[24]. For sequences that contained mixed signals of multiple subtypes,
the samples were considered to carry multiple Blastocystis subtypes. All
primers are listed in the Supplementary Material.
2.5. Deﬁnitions
Travel-related acquisition of Blastocystis was deﬁned as a combina-
tion of a negative PCR for Blastocystis in the pre-travel sample and a
positive PCR in the post-travel sample, or a positive PCR in both sam-
ples but for diﬀerent Blastocystis subtypes. Persistent carriers were de-
ﬁned as those with positive PCRs for the same subtype in both samples
and non-carriers as those with negative PCRs in both samples. Loss of
carriage was deﬁned as a positive pre-travel PCR and a negative PCR for
Table 1
Characteristics of included travellers (n= 479).
n %
Sex Female 263 54.9%
Male 216 45.1%
Age (median, range in years) 52 19–81
Chronic illness Yes 105 21.9%
Joint disorder 20 4.2%
>Cardiovascular disease 19 4.0%
Lung disease 18 3.8%
Bowel disease 10 2.1%
Multiple 8 1.7%
Diabetes 7 1.5%
Cancer 6 1.3%
Other 17 3.5%
No 374 78.1%
Antibiotic use within 3 months
before travel
Yes 45 9.4%
No 434 90.6%
Median duration of travel in
days (IQR)
18 (14–23)
Purpose of travel Holiday 395 82.5%
Work or internship 38 7.9%
Visiting friends or relatives 19 4.0%
Other 27 5.6%
Subregion visited during travel South Eastern Asia 69 14.4%
Eastern Africa 68 14.2%
Northern Africa 68 14.2%
Southern Africa 70 14.6%
Western Africa 67 14.0%
South America 67 14.0%
Southern Asia 70 14.6%
Accommodation during travel Hotel or apartment 121 25.3%
Luxury 109 22.8%
Low budget 53 11.1%
Family or local people 20 4.2%
Tent 12 2.5%
Several 146 30.5%
Other 18 3.7%
Traveller's diarrhoea Yes 183 38.2%
No 296 61.8%
Antibiotic use during travel Yes 28 5.8%
No 451 94.2%
Medical care during travel Visited doctor or hospital 16 3.3%
No medical care 463 96.7%
IQR, interquartile range.
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the same subtype in the post-travel sample. Because travellers who
were positive before travel could acquire Blastocystis of a diﬀerent
subtype, all travellers were considered ‘at risk’ for acquisition. All tra-
vellers that carried Blastocystis before travel were considered at risk for
losing Blastocystis.
Pre-travel diarrhoea and TD were deﬁned as 3 or more unformed
stools within 24 h, with or without accompanying symptoms.
2.6. Statistical analysis
Statistical analyses were done using IBM SPSS Statistics (version
24.0). Incidence proportions (IP) and incidence per 100 person-days of
travel (IR/100 pdt) and accompanying 95% CIs for acquisition and loss
were calculated for each subregion. If 95% CIs between subregions did
not overlap, the diﬀerence in acquisition and loss were considered
signiﬁcant. The association between carriage, acquisition and loss of
Blastocystis and antibiotic usage and TD was calculated with the Chi-
squared test (χ2) using MedCalc [25]. P-values below 0.05 were con-
sidered statistically signiﬁcant.
2.7. Mathematical modelling
Data on travel duration, time between pre- and post-travel sampling
and departure/return as well as the Blastocystis colonisation state before
and after travel were used in a mathematical model to estimate median
acquisition rates with 95% credibility intervals at home and during
travel, as well as decolonisation rates and duration of carriage. A de-
tailed description of this method has been included in the
Supplementary Material.
In short, we assume that individuals can be either colonised or
uncolonised. Colonised individuals may lose colonisation at a ﬁxed rate,
independent of whether the individual is travelling or at home.
Uncolonised individuals can acquire colonisation. The acquisition rate
depends on the location (during travel or at home) and the time an
individual spends at this location. If we put our data on the colonisation
status before and after travel, the time between sampling, the travel
duration and the subregion that were visited into a mathematical
Markov Chain Monte Carlo model, we are able to calculate loss of co-
lonisation, acquisition during travel for each of the included subregions
and acquisition at home.
3. Results
Of the 491 selected travellers, one or more samples were missing
from 7 subjects and samples of 5 subjects had negative IC-PCR's.
Therefore 479 travellers were included in further analyses.
Median travel duration was 18 days (IQR 14–23) and leisure
(82.5%) was the main purpose of travel. Travellers to Northern Africa
travelled shorter than those to other regions with median durations of
12 days (IQR 8–14) and 19 days (IQR 15–24), respectively. Travellers'
diarrhoea was reported by 183 travellers (38.2%) [Table 1].
Of the 479 travellers, 281 (58.7%) were negative before and after
travel. Before travel, 174 of the 479 travellers (36.3%) were already
carrying Blastocystis and in most of these (126 of 174; 72.4%) the same
subtype was persistently carried. In the remaining 48 travellers, no
Blastocystis or Blastocystis belonging to a diﬀerent subtype than before
travel were detected in the post-travel sample, indicating loss of
Blastocystis during travel (IP 27.6%; CI95 20.8–36.6% and IR 1.45/100
pdt; 1.07–1.92) [Fig. 1; Supplementary Table 1]. This included one
traveller who had lost two subtypes (ST1 and ST3) and one traveller
who had lost an ST1 and acquired an ST3 [Supplementary Table 2]. No
statistically signiﬁcant diﬀerences in the rates of loss between sub-
regions [Fig. 1, Supplementary Table 1] or between diﬀerent Blas-
tocystis subtypes were found (data not shown); however, numbers per
subregion and subtype were small [Supplementary Table 2].
Of 305 travellers who were negative before travel, 281 (92.1%)
were still negative after travel and 24 (7.9%; CI95 5.3–11.7%) acquired
Blastocystis. In addition, acquisition of another subtype was observed in
two travellers who carried Blastocystis before travel, resulting in a total
number of 26 acquisitions in the cohort of 479 travellers (5.4%; CI95
3.7%–8.0% and IR 0.28/100 pdt; 0.18–0.40). Acquisition rates were
highest in Southern Africa (IP 8.6%; IR 0.43/100 pdt) and lowest in
travellers to Eastern Africa (IP 2.9%; IR 0.15/100 pdt), but diﬀerences
were not statistically signiﬁcant [Fig. 1].
Before travel, ST1, ST2, ST3 and ST4 accounted for more than 90%
of all Blastocystis subtypes. ST3 was the most frequently carried sub-
type, present in 56/174 (32.2%) Blastocystis-positive subjects [Table 2].
Blastocystis ST1 and ST3 were the most frequently acquired subtypes
[Supplementary Table 2], but acquisition rates and rates of loss
[Table 2] were not statistically signiﬁcant between diﬀerent Blastocystis
subtypes. One traveller acquired a ST6/9 hybrid Blastocystis strain and
one acquired a Blastocystis that could not be subtyped due to technical
reasons.
Median travel duration and median time between pre- and post-
travel samples were comparable between non-carriers, persistent car-
riers and travellers with loss and acquisition [Supplementary Table 3].
Antibiotic use during travel was not associated with acquisition and
antibiotic use was slightly, but not signiﬁcantly, higher in non-carriers
than in travellers with acquisition (21/281 [7.5%] VS 1/26 [3.8%];
p=0.4934). In addition, antibiotic use was not associated with loss:
none of the 48 travellers that lost Blastocystis used antibiotics during
travel compared to 4 of 126 that were persistent carriers. One traveller
used nitrofurantoin and one used metronidazole during travel. Both
were non-carriers. No usage of antiparasitic nitazoxanide or fur-
azolidone was reported.
3.1. Association between Blastocystis carriage and TD
No association between Blastocystis acquisition and TD was found:
TD was reported in 10 of 26 travellers (38.5%) who acquired
Blastocystis and in 173 of 453 (38.2%) travellers who did not acquire
Blastocystis (p= 0.9779). Additionally, no association was found be-
tween loss of Blastocystis and TD: 19 of 47 (40.4%) travellers who lost
Blastocystis reported TD, compared to 44 of 125 (35.2%) persistent
carriers (p= 0.5274). Finally, there was no signiﬁcant diﬀerence in the
proportion of post-travel carriage between travellers that did and did
not report TD. Among those travellers that experienced TD, 54 of 183
(29.5%) carried Blastocystis post-travel and among travellers that did
not report TD, 97 of 296 (32.8%) were post-travel carriers
(p= 0.4558).
3.2. Mathematical modelling
Results of our mathematical model showed that the decolonisation
rate per day was 0.0110 (0.0081–0.01453) with a mean duration of
carriage of 91 days (95%CI 69–123). The chance of acquisition was
calculated to be 0.0041 per day during travel (95%CI 0.0014–0.0068)
and 0.0011 (0.0001–0.0043) per day when not travelling. Acquisition
rates were not signiﬁcantly diﬀerent between subregions.
[Supplementary table 4].
4. Discussion
This is the ﬁrst prospective longitudinal study addressing the dy-
namics of Blastocystis carriage during travel. We found high pre-travel
carriage rates and limited acquisition among travellers overall and for
each of the studied subregions. An interesting ﬁnding of this study is the
large proportion of travellers that appears to loose Blastocystis during
travel.
The ‘weighted selection’ strategy and the large sample size made it
possible to study acquisition in less visited sub regions. Ideally, multiple
samples should be taken to determine exactly when and where the
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Blastocystis were acquired and lost. However, multiple sampling during
travel however is a great challenge in terms of compliance and pre-
servation of the samples.
Theoretically, a small number of mixed infections, where one sub-
type is present in a much lower concentration than the other, could
have been missed by using this PCR- and sequencing-based method.
However, mixed infections up to a ratio of 1:10 can be detected with the
approach used in this study [unpublished data] and indeed a number of
subjects were found to have combined infections with 2 diﬀerent
Blastocystis subtypes.
The observed high rate of Blastocystis carriage of 36.3% before
travel and 31.5% after travel is comparable to rates reported for healthy
individuals in another Dutch study, but much higher than the pre-
valence among ulcerative colitis patients [26]. In a study in returning
travellers presented at one of our units (Center of Tropical Medicine
and Travel Medicine of the AMC, Amsterdam), a comparable proportion
carried Blastocystis was found in post-travel samples, but the proportion
was much lower in patients from other departments in the same hos-
pital [15].
In a case control study, investigating post-travel stool samples by
direct microscopy from 795 German tourists returning from tropical
countries, only 11.3% were found to be positive for Blastocystis [19].
Another non-prospective German study, performed between August
2006 and November 2009, found 14.9% of the travellers with TD and
3.6% of travellers without TD to be positive for Blastocystis (p= 0.03)
[18]. The lower post-travel prevalences compared to the present study
might be explained by the higher sensitivity of the PCR-based method
applied in our study as compared to microscopy.
The most frequently detected Blastocystis subtypes in our study were
subtypes 1–4, reﬂecting the most prevalent subtypes in humans. ST4
accounted for a relatively large proportion of 21.2% (32/151) of post-
travel carried subtypes. This is signiﬁcantly more than the 11.7% (12/
103) found in the before mentioned study in returning travellers in our
hospital (p= 0.0490) [15]. One traveller acquired a Blastocystis ST7,
which is possibly a zoonotic transmission from birds [27]. Subtype 6
and 9 are genetically similar and it is debated whether they should be
seen as variants of a single subtype [3,4]. The detection of a Blastocystis
subtype 6/9 hybrid in a traveller to Southeastern Asia may also indicate
that these subtypes form a continuum rather than distinct entities
[28–30]. As sample size was calculated to detect diﬀerences in acqui-
sition between subregions, the study was insuﬃciently powered to
detect diﬀerences in loss and acquisition per subtype.
Two mechanisms could potentially explain the observed acquisition
and loss of Blastocystis in this study. First, both could be related to
travel. Travel is potentially associated with an increased risk of acqui-
sition due to a higher prevalence, dissemination in the food chain and/
or lower hygiene standards at the travel destination. Theoretically,
travel could also result in loss of Blastocystis, for example by alterations
in intestinal microbiota that could be unfavourable for Blastocystis [31].
It is hypothesized that the presence of Blastocystis is a sign of a healthy
gut [32], although in our study no association between Blastocystis
carriage and TD was found.
Most likely, the observed acquisition and loss could merely reﬂect
the natural course of Blastocystis carriage. A few studies investigated
Blastocystis carriage in sequential samples. Vennila and colleagues, de-
scribed ﬂuctuation in the shedding of the parasite from day to day in
one patient [33]. In a Turkish randomized clinical trial on the eﬃcacy
of Saccharomyces boulardii and metronidazole for treatment of assumed
symptomatic Blastocystis infections, spontaneous clearance, as detected
by microscopy, was observed within 14 days in 4/15 children (26.7%)
receiving no treatment [34]. Of 17 Swiss placebo-treated children with
recurrent abdominal pain, 5 (29.4%) became microscopically negative
within 3 weeks [35]. These studies and our study found comparable
proportions of loss of carriage within a similar time frame. In our study,
Fig. 1. Acquisition and loss of Blastocystis per subregion visited. Blue box: acquisition rate (incidence proportions). Purple triangle: rate of loss (incidence pro-
portions). Black line: 95% conﬁdence interval (95%CI). In case 95%CI's do not overlap, the diﬀerence in rates is considered signiﬁcant.
Table 2
Pre and post travel carriage of Blastocystis subtypes.
Before travel After travel
Negative (loss) Positive (persistent carrier)
ST1 29 5 17.2% 24 82.8%
ST2 38 9 23.7% 29 76.3%
ST3 54 16 29.6% 38 70.4%
ST4 41 13 31.7% 28 68.3%
ST6 6 2 33.3% 4 66.7%
ST7 2 1 50.0% 1 50.0%
Mixeda 4 2 50.0% 2 50.0%
Total 174 48 27.6% 126 72.4%
Only subjects that carried Blastocystis before travel are shown. ST: subtype.
a Of these four travellers, one lost both an ST1 and ST3, one persistently
carried an ST2 and ST3, one lost an ST1 and acquired an ST3 and one persis-
tently carried an ST2 and additionally acquired an ST3 during travel.
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no statistically signiﬁcant diﬀerences in travel duration and the time
between samples were found between non-carriers, persistent carriers
and travellers with acquisition and loss, suggesting that Blastocystis
carriage can be relatively short-lived regardless of travel. In contrast,
individuals that were consistently positive for the same Blastocystis
strain (determined at allele level) over a time period ranging from 6 to
10 years have also been reported [36]. Future longitudinal studies in-
vestigating Blastocystis carriage in healthy, non-travelling individuals
could give insight in the natural course of Blastocystis carriage.
Our observation that the vast majority of Blastocystis detected after
travel were already carried before travel and only few travellers ac-
quired Blastocystis during travel, indicates that clinicians should be
reluctant to oﬀer treatment for Blastocystis carriage in returning tra-
vellers.
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